The Pathogenic Mechanism of α-Synucleinopathies and Development of Preventive/Therapeutic Drugs

Dear Colleagues,

α-Synucleinopathies are a group of neurodegenerative disorders characterized by the abnormal accumulation of α-synuclein protein in the brain. These disorders include Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. The pathogenesis of α-synucleinopathies is not completely understood, and societal issues are associated with both the diagnosis and treatment of these disorders. One of the primary factors in α-synucleinopathies is the cause of the abnormal accumulation of α-synuclein protein. Both genetic and environmental factors are involved; however, the exact mechanisms are still not well understood. Additionally, it is not yet clear whether the accumulation of α-synuclein is the cause of the neurodegeneration in these disorders or if it is a secondary effect. Another uncertainty is the lack of reliable biomarkers for α-synucleinopathies. Currently, the diagnosis of these disorders relies on clinical symptoms, which can be difficult to distinguish from other neurodegenerative diseases. Developing accurate biomarkers could lead to earlier diagnosis and better treatment options. Therefore, it is necessary to explore pathogenic mechanisms to find novel therapeutic targets and unique biomarkers.

This special issue aims to advance understanding of the pathogenic mechanism of α-synucleinopathies, including Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. The abnormal accumulation of α-synuclein protein is a hallmark of these disorders, but the exact mechanisms that lead to this accumulation and subsequent neurodegeneration are not yet fully understood. By studying the pathogenic mechanisms of these disorders, we hope to identify novel therapeutic targets for the development of effective treatments and investigate unique biomarkers to reveal their physiological significance. We welcome a wide range of topics, from basic science to clinical research on α-synucleinopathies.

Dr. Ichiro Kawahata and Dr. Kohji Fukunaga
Guest Editors

Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2200 USD. Submitted manuscripts should be well formatted in good English.